The AJMC® Type 1 Diabetes compendium is a comprehensive resource for news and interviews about this chronic autoimmune condition.
April 17th 2024
The connection was primarily established between type 1 diabetes (T1D) and the eating disorders bulimia and binge eating, with female patients with T1D at higher risk of insulin misuse as a result.
Dr Kevan Herold on Living With T1D: “There's Nothing You Do Without Thinking About It”
March 17th 2023It's harder for younger children to deal with the complexities of managing type 1 diabetes (T1D), so a delayed diagnosis even by a few years is a big deal, said Kevan Herold, MD, professor of immunobiology and medicine at Yale School of Medicine.
Watch
Limiting Teplizumab Coverage to First-Degree Relatives Is a Mistake, Says Dr Kevan Herold
March 3rd 2023Kevan Herold, MD, professor of immunobiology and medicine at Yale School of Medicine, talks about some insurers' requirement for patients to have a first-degree relative with type 1 diabetes to qualify for coverage of teplizumab.
Watch
Study Confirms Safety, Tolerability of Oral GABA for Type 1 Diabetes
February 23rd 2023A trial enrolling 97 children newly diagnosed with type 1 diabetes did not meet the primary endpoint of preservation of insulin production by beta cells, but it did show a significant decrease in fasting and clinically relevant reduced serum glucagon.
Read More
Glycemia Risk Index Measures Hypoglycemia, Hyperglycemia Risk in Patients With T1D
February 17th 2023The glycemia risk index (GRI) showed that pediatric patients and those receiving continuous subcutaneous insulin infusion had higher overall component of hypoglycemia than adults and those receiving multiple doses of insulin.
Read More
Nearly Identical Rates of Overweight, Obesity Between Adults With T1D, General Population
February 14th 2023Data showed that 64% of adults without any type of diabetes had overweight or obesity, compared with 62% of adults with type 1 diabetes (T1D) and 86% with type 2 diabetes between 2016 and 2021.
Read More
Family-Centered Interventions Improve Health Outcomes in Children, Adolescents With T1D
February 11th 2023Interventions in 9 studies were linked with varying effects on glycated hemoglobin, type 1 diabetes (T1D) management adherence, self-management behaviors, and parent-child teamwork in T1D management.
Read More
Female Adolescents With T1D Have Lower Quality of Life Than Male Children
January 27th 2023A systematic review evaluating sex differences in children with type 1 diabetes (T1D) found that female children had higher rates of comorbidities, higher body mass index, required higher insulin doses, and had a lower quality of life compared with male children.
Read More
T1D Community Helped Create T1D Index, Says JDRF's Tom Robinson
December 17th 2022Tom Robinson, vice president of global access at JDRF, talks about how the community and people living with type 1 diabetes (T1D) have contributed to the T1D Index, from development to publication and going forward.
Watch
T1D Index Will Be Updated Annually, JDRF’s Tom Robinson Explains
November 24th 2022Updating the Type 1 Diabetes (T1D) Index each year with the latest data and literature and implementing feedback is important for at least the first few years, said Tom Robinson, vice president of global access at JDRF.
Watch
JDRF's Tom Robinson Expands on Policies to Ensure Implementation, Access to Key T1D Interventions
November 19th 2022Get type 1 diabetes (T1D) communities involved in solving the problem and implementing T1D interventions in your country, said Tom Robinson, vice president of global access at JDRF.
Watch
JDRF's Tom Robinson Highlights Key T1D Interventions
November 16th 2022While each country has a different priority when it comes to type 1 diabetes (T1D) diagnosis and treatment, there is a fairly consistent outcomes checklist across nations, said Tom Robinson, vice president of global access at JDRF.
Watch
Study Details Effects of Off-Label GLP-1 RA, SGLT2 Inhibitor Use in Type 1 Diabetes
November 9th 2022An analysis of real-world data from a single medical center is providing insight into the effects of off-label glucagon-like peptide 1 (GLP-1) receptor agonist (RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitor use in people with type 1 diabetes.
Read More